- Home
- RLTY vs DSGN Comparison
RLTY vs DSGN Comparison
Compare RLTY & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- DSGN
- Stock Information
- Founded
- RLTY 2022
- DSGN 2017
- Country
- RLTY United States
- DSGN United States
- Employees
- RLTY N/A
- DSGN N/A
- Industry
- RLTY Investment Managers
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- DSGN Health Care
- Exchange
- RLTY Nasdaq
- DSGN Nasdaq
- Market Cap
- RLTY 259.2M
- DSGN 224.8M
- IPO Year
- RLTY N/A
- DSGN 2021
- Fundamental
- Price
- RLTY $15.10
- DSGN $3.45
- Analyst Decision
- RLTY
- DSGN Hold
- Analyst Count
- RLTY 0
- DSGN 1
- Target Price
- RLTY N/A
- DSGN $4.00
- AVG Volume (30 Days)
- RLTY 86.7K
- DSGN 131.3K
- Earning Date
- RLTY 01-01-0001
- DSGN 05-07-2025
- Dividend Yield
- RLTY 9.35%
- DSGN N/A
- EPS Growth
- RLTY N/A
- DSGN N/A
- EPS
- RLTY N/A
- DSGN N/A
- Revenue
- RLTY N/A
- DSGN N/A
- Revenue This Year
- RLTY N/A
- DSGN N/A
- Revenue Next Year
- RLTY N/A
- DSGN N/A
- P/E Ratio
- RLTY N/A
- DSGN N/A
- Revenue Growth
- RLTY N/A
- DSGN N/A
- 52 Week Low
- RLTY $11.38
- DSGN $2.60
- 52 Week High
- RLTY $14.60
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- RLTY 58.15
- DSGN 42.27
- Support Level
- RLTY $15.00
- DSGN $3.23
- Resistance Level
- RLTY $15.50
- DSGN $3.90
- Average True Range (ATR)
- RLTY 0.25
- DSGN 0.46
- MACD
- RLTY 0.07
- DSGN -0.07
- Stochastic Oscillator
- RLTY 75.31
- DSGN 11.20
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.